Miconazole therapy for treatment of fungal infections in cancer patients | Zendy

W. M. Jordan | Zendy; Gerald P. Bodey | Zendy; V. Rodríguez | Zendy; Steven J. Ketchel | Zendy; Jane E. Henney | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Miconazole therapy for treatment of fungal infections in cancer patients

Author(s) -

W. M. Jordan,

Gerald P. Bodey,

V. Rodríguez,

Steven J. Ketchel,

Jane E. Henney

Publication year - 1979

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.16.6.792

Subject(s) - miconazole , medicine , nausea , vomiting , toxicity , candida albicans , cancer , malignancy , candida tropicalis , pharmacotherapy , dermatology , antifungal , biology , microbiology and biotechnology

The effectiveness of miconazole was evaluated in 37 documented fungal infections, 32 of which were major infections. All patients were receiving therapy for advanced malignancy, with 28 patients having acute leukemia. The overall cure rate was 41% and it was also 41% for major fungal infections. Nine of 22 patients with Candida albicans infections were cured, and 3 of 11 patients with Candida tropicalis infections were cured. A total of 183 patients who received miconazole for presumed or documented fungal infection were evaluated for toxicity. Nausea and vomiting and central nervous system toxicity were the most common side effects, occurring in 25 and 16% of the patients, respectively. Overall, the drug was tolerated well, with only four patients requiring the drug to be permanently discontinued because of toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research